Diabetic retinopathy: Neuron protection as a therapeutic target

详细信息    查看全文

• 作者：Xinyuan Zhang^a ; ^d ; ^{xzhang@eye.usyd.edu.au} ; Ningli Wang^a ; ^{mmzxy@yahoo.com} ; Gaetano R. Barile^b ; Shisan Bao^c ; Mark Gillies^d
• 关键词：BNDF ; brain derived neurotrophic factor ; DR ; diabetic retinopathy ; DMO ; diabetic macular oedema ; ERG ; electroretinogram ; EPO ; Erythropoietin ; GABA ; gamma-amminobytyric acid ; GrB ; granzyme B ; PARP ; poly (ADP-ribose) polymerase ; Pp38MAPK ; phosphorylated p38
• 刊名：The International Journal of Biochemistry and Cell Biology
• 出版年：2013
• 出版时间：July, 2013
• 年：2013
• 卷：45
• 期：7
• 页码：1525-1529
• 全文大小：876 K

文摘

Diabetic retinopathy (DR) has mainly been regarded as a microvascular disease that is caused by hyperglycaemia and characterized by retinal vascular leakage, macular oedema and preretinal neovascularisation. Increasing clinical evidence from electroretinographic, contrast sensitivity, perimetric, and colour vision studies suggest that neuronal changes may occur prior to clinically detectable microvasculopathy. Thus, there may be a primary neurodegenerative process which contributes to loss of vision in DR. Neuronal apoptosis in DR has been reported both in vivo and in vitro. Consequently, neuroprotection in DR may be a valuable therapeutic target. This review outlines the recent new concepts of neurodegeneration in the pathogenesis of DR, particularly emphasising its potential for new therapeutic approaches.